Stereotaxis to uplist to NYSE American

The common shares of Stereotaxis (OTCQX:STXS) were approved for listing on the NYSE American exchange, effective with the opening on Sept. 6, with the same stock symbol. They will trade on the OTCQX until the close on Sept. 5.

“This is another milestone in our effort to improve awareness of our differentiated technology, clinical value, and growth opportunity,” David Fischel, chairman and CEO of Stereotaxis, said in a statement. “Listing on the NYSE American should support a more robust capital market for existing and new shareholders,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.